ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma

Benedetta Savino, Nicoletta Caronni, Achille Anselmo, Fabio Pasqualini, Elena M onica Borroni, Gianluca Basso, Giuseppe Celesti, Luigi Laghi, Athanasia Tourlaki, Vinicio Boneschi, Lucia Brambilla, Manuela Nebuloni, Gianluca Vago, Alberto Mantovani, Massimo Locati, Raffaella Bonecchi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

D6 is an atypical chemokine receptor acting as a decoy and scavenger for inflammatory CC chemokines expressed in lymphatic endothelial cells. Here, we report that D6 is expressed in Kaposi sarcoma (KS), a tumor ontogenetically related to the lymphatic endothelium. Both in human tumors and in an experimental model, D6 expression levels were inversely correlated with tumor aggressiveness and increased infiltration of proangiogenic macrophages. Inhibition of monocyte recruitment reduced the growth of tumors, while adoptive transfer of wild-type, but not CCR2(-/-) macrophages, increased the growth rate of D6-competent neoplasms. In the KS model with the B-Raf V600E-activating mutation, inhibition of B-Raf or the downstream ERK pathway induced D6 expression; in progressing human KS tumors, the activation of ERK correlates with reduced levels of D6 expression. These results indicate that activation of the K-Ras-B-Raf-ERK pathway during KS progression downregulates D6 expression, which unleashes chemokine-mediated macrophage recruitment and their acquisition of an M2-like phenotype supporting angiogenesis and tumor growth. Combined targeting of CCR2 and the ERK pathway should be considered as a therapeutic option for patients with KS.

Original languageEnglish
Pages (from-to)679-689
Number of pages11
JournalCancer immunology research
Volume2
Issue number7
DOIs
Publication statusPublished - Jul 1 2014

Fingerprint

Kaposi's Sarcoma
Down-Regulation
MAP Kinase Signaling System
Neoplasms
Macrophages
Growth
Lymphatic Endothelium
CC Chemokines
Adoptive Transfer
Chemokine Receptors
chemokine receptor D6
Chemokines
Monocytes
Theoretical Models
Endothelial Cells
Phenotype
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma. / Savino, Benedetta; Caronni, Nicoletta; Anselmo, Achille; Pasqualini, Fabio; Borroni, Elena M onica; Basso, Gianluca; Celesti, Giuseppe; Laghi, Luigi; Tourlaki, Athanasia; Boneschi, Vinicio; Brambilla, Lucia; Nebuloni, Manuela; Vago, Gianluca; Mantovani, Alberto; Locati, Massimo; Bonecchi, Raffaella.

In: Cancer immunology research, Vol. 2, No. 7, 01.07.2014, p. 679-689.

Research output: Contribution to journalArticle

Savino, Benedetta ; Caronni, Nicoletta ; Anselmo, Achille ; Pasqualini, Fabio ; Borroni, Elena M onica ; Basso, Gianluca ; Celesti, Giuseppe ; Laghi, Luigi ; Tourlaki, Athanasia ; Boneschi, Vinicio ; Brambilla, Lucia ; Nebuloni, Manuela ; Vago, Gianluca ; Mantovani, Alberto ; Locati, Massimo ; Bonecchi, Raffaella. / ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma. In: Cancer immunology research. 2014 ; Vol. 2, No. 7. pp. 679-689.
@article{2a86f885da34467d866b77b512966fe1,
title = "ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma",
abstract = "D6 is an atypical chemokine receptor acting as a decoy and scavenger for inflammatory CC chemokines expressed in lymphatic endothelial cells. Here, we report that D6 is expressed in Kaposi sarcoma (KS), a tumor ontogenetically related to the lymphatic endothelium. Both in human tumors and in an experimental model, D6 expression levels were inversely correlated with tumor aggressiveness and increased infiltration of proangiogenic macrophages. Inhibition of monocyte recruitment reduced the growth of tumors, while adoptive transfer of wild-type, but not CCR2(-/-) macrophages, increased the growth rate of D6-competent neoplasms. In the KS model with the B-Raf V600E-activating mutation, inhibition of B-Raf or the downstream ERK pathway induced D6 expression; in progressing human KS tumors, the activation of ERK correlates with reduced levels of D6 expression. These results indicate that activation of the K-Ras-B-Raf-ERK pathway during KS progression downregulates D6 expression, which unleashes chemokine-mediated macrophage recruitment and their acquisition of an M2-like phenotype supporting angiogenesis and tumor growth. Combined targeting of CCR2 and the ERK pathway should be considered as a therapeutic option for patients with KS.",
author = "Benedetta Savino and Nicoletta Caronni and Achille Anselmo and Fabio Pasqualini and Borroni, {Elena M onica} and Gianluca Basso and Giuseppe Celesti and Luigi Laghi and Athanasia Tourlaki and Vinicio Boneschi and Lucia Brambilla and Manuela Nebuloni and Gianluca Vago and Alberto Mantovani and Massimo Locati and Raffaella Bonecchi",
year = "2014",
month = "7",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0202",
language = "English",
volume = "2",
pages = "679--689",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma

AU - Savino, Benedetta

AU - Caronni, Nicoletta

AU - Anselmo, Achille

AU - Pasqualini, Fabio

AU - Borroni, Elena M onica

AU - Basso, Gianluca

AU - Celesti, Giuseppe

AU - Laghi, Luigi

AU - Tourlaki, Athanasia

AU - Boneschi, Vinicio

AU - Brambilla, Lucia

AU - Nebuloni, Manuela

AU - Vago, Gianluca

AU - Mantovani, Alberto

AU - Locati, Massimo

AU - Bonecchi, Raffaella

PY - 2014/7/1

Y1 - 2014/7/1

N2 - D6 is an atypical chemokine receptor acting as a decoy and scavenger for inflammatory CC chemokines expressed in lymphatic endothelial cells. Here, we report that D6 is expressed in Kaposi sarcoma (KS), a tumor ontogenetically related to the lymphatic endothelium. Both in human tumors and in an experimental model, D6 expression levels were inversely correlated with tumor aggressiveness and increased infiltration of proangiogenic macrophages. Inhibition of monocyte recruitment reduced the growth of tumors, while adoptive transfer of wild-type, but not CCR2(-/-) macrophages, increased the growth rate of D6-competent neoplasms. In the KS model with the B-Raf V600E-activating mutation, inhibition of B-Raf or the downstream ERK pathway induced D6 expression; in progressing human KS tumors, the activation of ERK correlates with reduced levels of D6 expression. These results indicate that activation of the K-Ras-B-Raf-ERK pathway during KS progression downregulates D6 expression, which unleashes chemokine-mediated macrophage recruitment and their acquisition of an M2-like phenotype supporting angiogenesis and tumor growth. Combined targeting of CCR2 and the ERK pathway should be considered as a therapeutic option for patients with KS.

AB - D6 is an atypical chemokine receptor acting as a decoy and scavenger for inflammatory CC chemokines expressed in lymphatic endothelial cells. Here, we report that D6 is expressed in Kaposi sarcoma (KS), a tumor ontogenetically related to the lymphatic endothelium. Both in human tumors and in an experimental model, D6 expression levels were inversely correlated with tumor aggressiveness and increased infiltration of proangiogenic macrophages. Inhibition of monocyte recruitment reduced the growth of tumors, while adoptive transfer of wild-type, but not CCR2(-/-) macrophages, increased the growth rate of D6-competent neoplasms. In the KS model with the B-Raf V600E-activating mutation, inhibition of B-Raf or the downstream ERK pathway induced D6 expression; in progressing human KS tumors, the activation of ERK correlates with reduced levels of D6 expression. These results indicate that activation of the K-Ras-B-Raf-ERK pathway during KS progression downregulates D6 expression, which unleashes chemokine-mediated macrophage recruitment and their acquisition of an M2-like phenotype supporting angiogenesis and tumor growth. Combined targeting of CCR2 and the ERK pathway should be considered as a therapeutic option for patients with KS.

UR - http://www.scopus.com/inward/record.url?scp=84922671203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922671203&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0202

DO - 10.1158/2326-6066.CIR-13-0202

M3 - Article

C2 - 24844911

AN - SCOPUS:84922671203

VL - 2

SP - 679

EP - 689

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 7

ER -